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Background: Neurofibromatosis type 1 (NF1) is a common autosomal dominant genetic disorder with significant
impact on health-related quality of life (HRQOL). Research in understanding the pathogenetic mechanisms of
neurofibroma development has led to the use of new clinical trials for the treatment of NF1. One of the most
important outcomes of a trial is improvement in quality of life, however, no condition specific HRQOL instrument
for NF1 exists. The objective of this study was to develop an NF1 HRQOL instrument as a module of PedsQL™ and
to test for its initial feasibility, internal consistency reliability and validity in adults with NF1.
Methods: The NF1 specific HRQOL instrument was developed using a standard method of PedsQL™ module
development – literature review, focus group/semi-structured interviews, cognitive interviews and experts’ review of
initial draft, pilot testing and field testing. Field testing involved 134 adults with NF1. Feasibility was measured by
the percentage of missing responses, internal consistency reliability was measured with Cronbach’s alpha and
validity was measured by the known-groups method.
Results: Feasibility, measured by the percentage of missing responses was 4.8% for all subscales on the adult
version of the NF1-specific instrument. Internal consistency reliability for the Total Score (alpha =0.97) and subscale
reliabilities ranging from 0.72 to 0.96 were acceptable for group comparisons. The PedsQL™ NF1 module
distinguished between NF1 adults with excellent to very good, good, and fair to poor health status.
Conclusions: The results demonstrate the initial feasibility, reliability and validity of the PedsQL™ NF1 module in
adult patients. The PedsQL™ NF1 Module can be used to understand the multidimensional nature of NF1 on the
HRQOL patients with this disorder.
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Neurofibromatosis type 1 (NF1) is a common autosomal
dominant genetic disorder with a prevalence of 1 in
3000 persons worldwide, independent of gender, race
and ethnicity [1-4]. According to National Institutes of
Health, NF1 is diagnosed by the presence of two or
more of the following clinical features – 1) six or more
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reproduction in any medium, provided the ordiameter), 2) two or more neurofibromas of any type or
one plexiform neurofibroma, 3) freckling in the axillary
or inguinal regions, 4) optic glioma, 5) two or more
Lisch nodules, 6) a distinctive osseous lesion (sphenoid
dysplasia or thinning of the long bone cortex with
or without pseudarthrosis), 7) having a first degree
relative with NF1 [5,6]. NF1, also known as von
Recklinghausen’s disease, is characterized by the pres-
ence of multiple cutaneous neurofibromas, café au lait
spots, intertriginous freckling, and Lisch nodules (iris
hamartomas) [7]. Almost one half of the affected
individuals with this disorder have been shown to have
learning disabilities [8]. Other common findings include
optic gliomas, bony abnormalities, headache and hyper-Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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NF1 include malignant peripheral nerve sheath tumors,
brain tumors, vasculopathy, epilepsy, growth problems,
neurological dysfunction and pruritus [1,7-9].
Neurofibromas, pathognomonic for NF1, are benign
nerve sheath tumors that can be extraneural or intraneural.
They are composed of Schwann cells, perineural cells,
fibroblasts, and mast cells [10,11]. They may remain asymp-
tomatic or can cause a wide variety of symptoms including
pain, pruritus, paresthesias (tingling, numbness) and local
trauma. Extraneural neurofibromas cause cosmetic disfig-
urement whereas internal neurofibromas impinge on
neighboring organs and significantly increase morbidity and
mortality [12,13]. Childhood through early adulthood is a
critical period for the accelerated growth of neurofibromas
[1,14]. Rapid tumor growth also occurs during pregnancy
due to associated hormonal changes [12,14]. The variable
nature of neurofibromas and other symptoms associated
with NF1 have a significant impact on the health-related
quality of life (HRQOL) of individuals with this disorder
[15,16].
NF1 is a lifelong, progressive, variable and unpredictable
disorder [17]. The main stay of treatment for NF1 is sup-
portive or surgical. However, surgical removal of neuro-
fibromas is unsatisfactory as these tumors often regrow
and the underlying cause has not been treated [14,18].
Progress in understanding the genetics and pathogenetic
mechanisms has led to the use of new drugs for the treat-
ment of NF1 and the emergence of a number of clinical
trials [11,19]. Participants in these clinical trials need ob-
jective follow up to monitor changes in clinical symptoms.
Radiographic imaging (3-dimensional MRI) is being done
with some success however, defining success from
calculations of tumor mass from radiographic imaging is
difficult as neurofibromas have irregular shapes and may
be fibrotic [14]. Thus, they may not show a significant de-
crease in size with treatments despite the report of im-
provement in clinically significant symptoms [18]. Patients
with little tumor shrinkage have anecdotally reported large
improvements in functioning and well-being that could be
measured with a NF1 specific HRQOL instrument.
HRQOL is arguably one of the most important mea-
sures in evaluating effectiveness of clinical treatments
[20,21]. HRQOL instruments used in previous studies in
patients with NF1 have been generic and may be useful
for comparing across different health conditions. Studies
of generic instruments showed that NF1 had a significant
impact on all domains of the Short Form 36 health sur-
vey (SF-36) when compared to the normative population
[15,16]. Limitations exist to generic quality of life sur-
vey instruments when they are applied to patients with
specific illnesses [22]. Generic instruments do not mea-
sure disease-specific HRQOL, for instance, skin paresthe-
sias in individuals with NF1. In contrast, disease-specificinstruments measure the impact of specific symptoms and
are more sensitive for the detection and quantification of
small changes over time [22]. A significant gap in the
current empirical literature is the lack of a validated NF1-
specific HRQOL instrument. Consequently, the objective
of this study was to develop an NF1 specific HRQOL in-
strument (as a Module of the PedsQL™) and to test for its
initial feasibility, internal consistency reliability and valid-
ity. We hypothesized that HRQOL when measured by the
PedsQL™ NF1 Module domains would be associated with
the self-reported health status.
Methods
Human subjects ethics for this study was reviewed and
approved by the Indiana University Institutional Review
Board and in compliance with the Helsinki Declaration. In
accordance with HRQOL instrument development
protocols, the PedsQL™ NF1 Module was designed
through the following five phases – 1) literature review; 2)
outline of the instrument; 3) pilot instrument develop-
ment – a) focus group/semi-structured interviews, b) cog-
nitive interviews, c) experts’ review; 4) pilot testing and 5)
field testing.
Phase 1 – literature review
We conducted an extensive literature search in Pub Med
database for symptoms and signs of NF1 [5-9,23-34]
(complete search methods and table of references avail-
able on request). The HRQOL literature was reviewed
for measures pertinent to NF1 [35-39].
Phase 2 – outline of the instrument
Clinicians taking care of patients with NF1 at Indiana Uni-
versity Hospitals, Indianapolis, IN, were interviewed to
learn about their experiences with NF1. An initial outline
of the instrument was developed based on literature re-
view and clinicians’ experiences. Pertinent questions were
drawn from the existing PedsQL™ Arthritis, Cancer, Cere-
bral Palsy and Family Impact Modules [36-39]. Instrument
domains were designed to address HRQOL issues specific
to NF1.
Phase 3 – pilot instrument development
The initial instrument was modified after conducting a
focus group or semi-structured interview, cognitive
interviews and experts’ review. a) Focus group/Semi-
structured interview: Information about the focus group
was advertised in the NF clinic at Indiana University
Hospitals. Individuals were enrolled into the focus group
if they had NF1 and were willing to talk about their
disorder and its effect on their health and well-being.
Written-informed consent was obtained from all par-
ticipants. We conducted one focus group of three
individuals and 2 semi-structured interviews with two
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about how NF1 affected their health and well-being. All
interviews were digitally recorded, transcribed and de-
identified for research purposes. By interpretative phe-
nomenological analysis [40,41], new domains were iden-
tified from the focus group/semi-structured interviews,
specifically, Skin Irritation, Sensation, Movement and
Balance and Sexual Functioning. b) Cognitive interviews:
An initial draft instrument was administered at the NF
clinic. Cognitive interviewing of the participants was done
to find out problems with wording of items, interpretation
of instructions and to estimate the time required to
complete the surveys. The items were revised after receiv-
ing the participants’ feedback. c) Experts’ review: The modi-
fied instrument was further reviewed by NF1 researchers
and clinicians. After cognitive interviews and expert
reviews, additional changes were made which included
rewording “sensitive skin” to “rough skin” in the Skin Irrita-
tion domain and adding “not applicable” as a choice in the
Sexual Functioning domain. The pilot instrument
developed as a result has 16 domains and 74 items.
The 74-item PedsQL™ NF1 Module: Adult self- report
instrument comprises 16 domains/subscales: 1) Physical
Functioning (8 items), 2) Emotional Functioning (5
items), 3) Social Functioning (3 items), 4) Cognitive
Functioning (5 items), 5) Communication (3 items),
6) Worry (7 items), 7) Perceived Physical Appearance
(3 items), 8) Pain and Hurt (3 items), 9) Paresthesias
(2 items), 10) Skin Irritation (5 items), 11) Sensation (4
items), 12) Movement and Balance (4 items), 13) Daily
Activities (12 items), 14) Fatigue (3 items), 15) Treat-
ment Anxiety (4 items) and 16) Sexual Functioning
(3 items).
The NF1 HRQOL format, instructions, and Likert re-
sponse scale are similar to the PedsQL™ 4.0 Generic Core
Scales and other PedsQL™ Disease-Specific Modules. Al-
though originally developed for use in children, the
PedsQL™ format has been extended to adults with a gen-
eric instrument as well as several disease specific
instruments [35]. The instructions ask how much of a
problem each item has been during the past one month.
A 5-point response scale is used for all items (0 = never a
problem, 1 = almost never a problem, 2 = sometimes a
problem, 3 = often a problem, 4 = almost always a prob-
lem). Items are reverse scored and linearly transformed to
a scale of 0–100 similar to PedsQL™ 4.0 Generic Core
Scales (0 = 100, 1 = 75, 2 = 50, 3 = 25, 4 = 0) [35]. Hence,
higher scores signify better HRQOL [42,43] and fewer
symptoms or problems. The Total Score is computed as
the sum of all items on the PedsQL™ NF1 Module divided
by the number of items answered (this accounts for
missing data). Subscale scores are computed as the sum of
the items divided by the number of items that were
answered in that subscale. If more than 50% of the itemsin the subscale are missing, the subscale score is not
computed [44]. Information about demographics is not
included in the instrument except for age of the partici-
pant. In addition, participants were asked to rate their
health status on a Likert scale as – excellent, very good,
good, fair, or poor.
Phase 4 – pilot testing
The PedsQL™ NF1 pilot instrument was tested at the
Children’s Tumor Foundation sponsored NF forum in July
2011 in Minnesota, to check for the initial feasibility and
internal consistency reliability. All participants with NF1
who were not involved in prior phases of instrument de-
velopment, were encouraged to fill out the surveys. A
sample of 10 adults with NF1 completed the surveys.
The mean age of the participants was 40.5 y (range 20 to
62 y). Feasibility was measured by the average time taken
to complete the survey and by the percentage of missing
responses [44]. Internal consistency reliability was mea-
sured by computing Cronbach’s coefficient alpha [45].
Pilot testing showed that, on an average, participants took
6 minutes to complete the survey (range 4 to 8 min). The
missing response rate was 2.3% (n = 17), with the Sexual
Functioning domain having the highest number of missing
responses (n = 10). Two participants were missing 1
response in Physical Functioning, one participant was
missing 3 responses in Perceived Physical Appearance,
one participant was missing 1 response and three parti-
cipants were missing all 3 responses in the Sexual
Functioning domain. The Worry and Movement & Bal-
ance domains each had 1 missing response. Total scale
internal consistency reliability was 0.82, showing adequate
initial internal consistency of the instrument. Pilot testing
provided initial support with adequate feasibility and in-
ternal consistency to proceed to the next phase of instru-
ment development.
Phase 5 – field testing
This final phase consisted of a larger NF1 sample across
the country to determine feasibility, reliability and valid-
ity of PedsQL™ NF1 Module scales.
Sample & setting
Participants were recruited from the NF clinic at Indiana
University hospitals and national NF1 conferences from
July 2011 to February 2012. In addition, the NF1 module
for adults was placed online and web-links were adver-
tised through NF organizations by publishing informa-
tion about the study in their newsletters and websites
(NF Midwest and Texas NF foundation). A sample of
124 adults completed the surveys. Pilot surveys (n = 10)
are included in this sample since they showed no signifi-
cant difference in mean subscale scores by independent
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was 40.2 years, ranging from 20 to 71 years.Statistical analysis
Scale internal consistency reliability was determined by
calculating Cronbach’s coefficient alpha [45]. For each
subscale, “Cronbach’s alpha if item deleted” was deter-
mined to see if subscale reliability improves with the
removal of the item. Subscale reliabilities of 0.70 or
more are recommended for comparing patient groups,
whereas reliability of 0.90 is recommended for analyzing
individual patient scale scores [46,47]. Considering the
small sample size, the Sexual Functioning domain was
excluded from the analyses as it had the highest missing
responses. Exploratory factor analysis using Promax ro-
tation was conducted for the remaining 71 items. Item
loadings were assessed using a cut-off value of 0.30 to
see whether items loaded high on one and only one fac-
tor (i.e., ‘simple structure’) and whether the collection of
items that loaded high on each factor formed a concep-
tually relevant subscale.
Feasibility was measured by the percentage of missing
values [44]. Multitrait scaling analysis was performed to
find out the extent to which individual items correlated
with the hypothesized subscale construct rather than
with other subscales [48]. We also examined the item-
hypothesized subscale correlations (corrected by remov-
ing the item from the Total Score) and we used a cutoff
of 0.40 or higher for indicating good item discrimination
[44,45]. Multitrait scaling analyses were summarized via
tests of individual item scaling success, defined as the
number of times an item correlated higher with its
hypothesized subscale construct rather than with an-
other subscale by ≥ 2 standard errors [44], which
provided an approximation of scaling success. The per-
centage of item scaling successes relative to the total
number of item scaling tests was calculated for each
subscale [44,49].
Construct validity of the instrument was determined
using the known-groups method, which compares sub-
scale scores across groups known to differ in the health
construct being investigated [44,50]. NF1 participants
were divided into 3 groups based on their self-reported
health status – ‘excellent to very good’ (n = 47), ‘good’
(n = 46), and ‘fair to poor’ (n = 41). Mean subscale
scores were compared among these 3 groups using one-
way ANOVA. Effect sizes were calculated for the
subscale scores to estimate the magnitude of differences.
Effect sizes are designated as small (.20), medium (.50)
and large (.80) in magnitude [51]. Statistical analyses
were done using SPSS 18 version for Windows (SPSS
Inc., Chicago IL, USA) and SAS 9.3 version for Windows
(SAS Institute Inc., Cary, NC, USA).Results
Item reduction
Based on the combined results of item-test statistics
while determining reliability and exploratory factor
analysis, 4 items were deleted from the following sub-
scales of the instrument – “having headaches (Phy-
sical Functioning), feeling isolated from others (Social
Functioning), worry about keeping or doing a job
(Worry) and managing my NF1 (Treatment Anxiety).
The final instrument reported in this manuscript has 16
subscales and 70 items (including the Sexual Func-
tioning domain) as shown in Appendix A.
Feasibility
Feasibility, measured by the percentage of missing
responses was 4.8% for all subscales on the adult version
of the PedsQL™ NF1 Module. The Sexual Functioning
subscale had the highest number of missing responses
(124, 30.8%) and was not included in any statistical
analyses.
Item-internal consistency
Item-subscale correlations showed that all items on the
adult version of the PedsQL™ NF1 Module exceeded our
criterion (0.40) for item discrimination, except for one
item on the Worry subscale (worry about future or the
risk of having children with NF1) with a correlation of
0.34. We retained this item in the final version of the
PedsQL™ NF1 Module, however, because it was deemed
important by the NF1 adults during the focus group/
semi-structured interviews and by NF1 experts.
Item scaling tests
The results of scaling tests for the adult version of the
PedsQL™ NF1 Module are shown in Table 1. The scaling
success for Cognitive Functioning was highest with
100% and lowest for Social Functioning at 42.86%. The
mean and median of scaling success for all the subscales
of the adult version of the PedsQL™ NF1 Module was
73% and 71.4% respectively.
Internal consistency reliability
Table 2 shows internal consistency reliability coefficients
for all subscales of the Adult PedsQL™ NF1 Module.
Subscale reliabilities ranged from 0.72 to 0.96, with all
subscales exceeding the minimum reliability criterion of
0.70 required for group comparisons. Total Score was
0.97, which exceeded the reliability criterion of 0.90
recommended for analyzing individual patient scores.
Construct validity
Table 3 compares mean subscale scores and effect sizes
of three groups of NF1 participants based on their self-
reported health status. Total Scores of the three groups
Table 1 Item scaling tests for the adult PedsQL™ NF1 module subscalesª
Subscale
Itemsb
Range of item correlations Item scaling tests
Item-Internal consistencyc Item-Discriminant validityd # Success/Totale Scaling success rate (%)
Physical Functioning 7 .69-.85 .01 -.67 72/98 73.47
Emotional Functioning 5 .69-.85 .18 -.52 64/70 91.43
Social Functioning 2 .58 .14 -.47 12/28 42.86
Cognitive Functioning 5 .77-.90 .08-.46 70/70 100
Communication 3 .58-.81 .12 -.49 38/42 90.48
Worry 6 .34-.79 .01 -.56 51/84 60.71
Perceived Physical Appearance 3 .72-.85 .02 -.55 38/42 90.48
Pain and Hurt 3 .80-.93 .15 -.76 25/42 59.52
Paresthesias 2 .77 .16 -.72 16/28 57.14
Skin Irritation 5 .48-.76 .08 -.53 39/70 55.71
Sensation 4 .43-.64 .04 -.46 39/56 69.64
Movement and Balance 4 .74-.84 .08 -.69 38/56 67.86
Daily Activities 12 .59-.89 .01 -.65 140/168 83.33
Fatigue 3 .78-.83 .21-.60 30/42 71.43
Treatment Anxiety 3 .55-.86 .11 -.45 34/42 80.95
a n = 134, Standard error = 0.09.
b Number of items and number of item-internal consistency tests per subscale.
c Correlations between items and hypothesized subscale corrected for overlap.
d Correlations between items and other subscales.
e Number of hypothesized significantly higher/total number of correlations.
Table 2 Reliability and descriptive statistics for the adult
PedsQL™ NF1 module
Domain Items Sample Mean ± SD α
Physical Functioning 7 133 63.21 ± 28.75 .93
Emotional Functioning 5 134 51.53 ± 25.10 .92
Social Functioning 2 134 60.91 ± 27.40 .73
Cognitive Functioning 5 134 52.42 ± 25.14 .94
Communication 3 127 66.21 ± 27.38 .84
Worry 6 127 42.66 ± 24.83 .83
Perceived Physical Appearance 3 126 38.96 ± 33.41 .90
Pain and Hurt 3 127 53.61 ± 33.03 .93
Paresthesias 2 127 58.86 ± 31.38 .87
Skin Irritation 5 127 65.39 ± 25.03 .83
Sensation 4 124 67.14 ± 24.16 .72
Movement and Balance 4 125 72.60 ± 27.88 .91
Daily Activities 12 124 89.38 ± 20.09 .96
Fatigue 3 124 51.75 ± 28.42 .90
Treatment Anxiety 3 124 75.20 ± 25.95 .87
Total Score 67 134 63.07 ± 17.86 .97
Higher values equal better health-related quality of life. SD, standard deviation;
α, Cronbach’s coefficient alpha.
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score among NF1 participants with ‘fair to poor’ health
status. All subscale scores of the instrument were signifi-
cantly different among the three groups, supporting ini-
tial discriminant validity of the PedsQL™ NF1 Module.
Effect sizes ranged from 0.22 to 0.63, with the largest
effect sizes for the Pain and Hurt subscale, and the
lowest effect sizes for the Perceived Physical Appearance
subscale. The majority of the effect sizes were in
medium range supporting discriminant validity of the
individual subscales.Discussion
The present study provides support for the initial feasibility,
reliability and validity of the PedsQL™ NF1 Adult Version in
a general population of adults with NF1. The adult version
of the PedsQL™ NF1 Module could be completed in 6 -
minutes and demonstrated minimal missing values,
supporting the feasibility of the instrument. The majority of
the missing responses were shown for the Sexual
Functioning subscale, which was not included in statistical
analyses. We included this domain in the instrument in the
appendix since it was reflective of concerns expressed by the
majority of patients during the focus group/semi-structured
interviews and may be an important area of improvement
with newer therapies. Internal consistency for the Adult
PedsQL™ NF1 Module Total Score exceeded the minimum
reliability criterion of 0.90 for individual patient analysis,
Table 3 Comparison of mean subscale scores among 3 groups of NF1 participants based on self-reported health status
Subscale Excellent - Very good Good Fair - Poor p-
value*
Effect
sizeN Mean ± SD N Mean ± SD N Mean ± SD
Physical Functioning 46 79.66 ± 24.79 46 64.51 ± 25.99 41 43.29 ± 23.61 <.0001 .51
Emotional Functioning# 47 60.64 ± 21.86 46 52.17 ± 26.32 41 40.37 ± 23.25 .001 .33
Social Functioning# 47 72.34 ± 26.57 46 59.78 ± 28.86 41 49.09 ± 21.17 <.0001 .35
Cognitive Functioning# 47 58.40 ± 26.66 46 54.02 ± 24.35 41 43.75 ± 22.25 .020 .24
Communication# 46 74.28 ± 26.11 43 65.50 ± 26.39 38 57.24 ± 27.75 .016 .25
Worry 46 51.38 ± 24.77 43 44.77 ± 24.65 38 29.71 ± 19.79 <.0001 .36
Perceived Physical Appearance# 46 46.92 ± 34.26 42 39.48 ± 35.69 38 28.73 ± 27.31 .044 .22
Pain and Hurt 46 74.09 ± 28.45 43 58.53 ± 25.10 38 23.25 ± 22.77 <.0001 .63
Paresthesias 46 73.10 ± 30.61 43 65.41 ± 25.71 38 34.21 ± 23.19 <.0001 .53
Skin Irritation 46 77.83 ± 20.46 43 65.23 ± 22.47 38 50.53 ± 25.14 <.0001 .44
Sensation# 45 74.03 ± 21.48 42 67.26 ± 22.51 37 58.61 ± 26.82 .015 .26
Movement and Balance 46 87.91 ± 20.04 42 74.26 ± 21.08 37 51.69 ± 30.29 <.0001 .53
Daily Activities 46 95.61 ± 15.45 42 94.49 ± 16.13 36 75.46 ± 22.91 <.0001 .45
Fatigue 46 63.04 ± 27.81 42 58.93 ± 24.72 36 28.94 ± 19.05 <.0001 .52
Treatment Anxiety 46 82.79 ± 23.33 42 77.78 ± 23.47 36 62.50 ± 27.78 .001 .32
Total Score 47 74.37 ± 14.03 46 64.63 ± 15.64 41 48.37 ± 13.60 <.0001 .59
*p-values based on one-way ANOVA. Higher values equal better health-related quality of life. Effect sizes are designated as small (0.20), medium (0.50) and large
(0.80). SD, standard deviation. # Except for these, Fair-Poor health status group was different from other two groups with p < .05 by Bonferroni test.
Nutakki et al. Health and Quality of Life Outcomes 2013, 11:21 Page 6 of 9
http://www.hqlo.com/content/11/1/21which supports the use of a Total Score as a measure of
HRQOL in NF1 adults and supports the use of this instru-
ment to follow improvement or deterioration over time in
individuals. The individual subscale scores ranged from .72
to .96, which suggest that each subscale can be used to
examine the specific domains of the PedsQL™ NF1 Module
as well as using the Total Score for an overall assessment of
NF1-specific HRQOL.
The adult version of PedsQL™ NF1 Module was able to
differentiate among patients with varying overall health sta-
tus. These findings support the initial discriminant validity
of the Adult PedsQL™ NF1 Module. Consistent with our
hypothesis, lower scores on the Adult PedsQL™ NF1 Mod-
ule domains were associated with adult patients’ self-
reported ‘fair’ to ‘poor’ health status. Adult patients with
‘excellent’ to ‘very good’ health status had higher HRQOL
scores when compared to the other two health status
groups across all subscales. The study sample has a mixture
of participants from both clinical populations and general
NF1 populations. The greatest difference in mean subscale
scores existed in the Pain and Hurt subscale (50.84), which
demonstrates that a clinic population reports more pain
compared to rest of the participants. The Cognitive
Functioning subscale (14.65) showed minimal differences
among the groups. Although cognitive impairment is a fre-
quent finding in NF1 [52], it is likely that the clinic group is
presenting for physical symptoms.
Our study has several strengths, including the diver-
sity of sample, nation-wide representation of theparticipants (clinic populations from states in and
around Indiana, and a general NF1 population by ad-
vertising the study at national conferences and
organizations) and broad age range (20-71 years) of
participants in the field test. The Adult PedsQL™ NF1
Module can be self-administered, read easily (designed
at the sixth grade reading level) and filled out quickly.
Although the Module appears lengthy with 16 domains
and 70 items, participants took an average of 6 minutes
to complete it in pilot testing.
Our study also has some limitations. First of all, the
sample size was somewhat small for a field test, which
limits the precision of our factor analysis when redu-
cing the number of items. Secondly, for divergent val-
idity, we used participants self-reported health status
and hence, there exists the possibility of overestimat-
ing or underestimating the actual disease severity. The
Social Functioning subscale in the Adult PedsQL™ NF1
Module was problematic with a low scaling success.
Although, we originally had 3 items in this subscale,
one item was dropped to improve the subscale internal
consistency. In future versions of this instrument we
recommend testing more Social Functioning items as
well as the Sexual Functioning items.
Currently, we are developing teen report and parent
proxy report versions of the NF1 instrument. In the fu-
ture, we plan to follow the strict methodology for
PedsQL™ instrument development to validate child, teen
and parent versions of the instrument.
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In summary, the adult version of PedsQL™ NF1 Module
can be used to understand the multidimensional nature
of NF1 on the HRQOL patients with this disorder and
may assist in medical decision making. The instrument
demonstrates initial feasibility, reliability, and discrimin-
ant validity.Appendix A
PedsQL™ NF1 Module-Adult report
Physical Functioning
1. Feeling physically weak
2. Walking more than one block
3. Climbing stairs
4. Running
5. Doing a sports activity or exercise
6. Lifting something heavy
7. Doing chores around the house
Emotional Functioning
1. Feeling anxious
2. Feeling sad
3. Feeling angry
4. Feeling frustrated
5. Feeling helpless or hopeless
Social Functioning
1. Getting support from others
2. Having enough energy for social activities
Cognitive Functioning
1. Keeping attention on things
2. Remembering what people tell you
3. Remembering what you just heard/read
4. Thinking quickly
5. Remembering what you were just thinking
Communication
1. Telling the doctors and nurses how you feel
2. Asking the doctors and nurses questions
3. Talking with others about your disorder
Worry
1. Worrying about my neurofibromas
2. Worrying about side effects from medical treatments
3. Worrying about whether or not medical treatments
are working
4. Worrying that neurofibromas will grow bigger or reoccur
5. Worrying about my future or the risk of having
children with Neurofibromatosis type 1
6. Worrying about the risk of other health related issues
associated with Neurofibromatosis type 1Perceived Physical Appearance
1. Feeling that I am not good looking
2. Not wanting other people to see my neurofibromas
3. Being embarrassed about others seeing my body
Pain and Hurt
1. Aching or hurting
2. Aching or hurting a lot
3. Not sleeping because of pain
Paresthesias
1. A burning sensation in some part of my body
2. A tingling sensation in some part of my body
Skin Irritation
1. Itching
2. Itching a lot
3. Getting a skin rash when exposed to sun
4. Tolerating temperature changes
5. Rough skin
Sensation
1. Vision in one or both eyes
2. Seeing well enough with glasses or contact lenses
3. Hearing in one or both ears
4. Speech
Movement and Balance
1. Bending my body
2. Moving one or both legs
3. Using or moving one or both arms
4. Keeping balance when sitting or standing
Daily Activities
1. Putting on shoes
2. Buttoning my shirt
3. Combing my hair
4. Getting into the bathroom to use the toilet
5. Undressing to use the toilet
6. Getting in and out of bathtub or shower
7. Brushing my teeth
8. Eating with a fork and knife
9. Using a phone
10. Shopping
11. Managing money
12. Driving
Fatigue
1. Feeling tired
2. Resting a lot
3. Having enough energy to do things that I like to do
Treatment Anxiety
1. Getting scared about going to the doctor
Nutakki et al. Health and Quality of Life Outcomes 2013, 11:21 Page 8 of 9
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3. Being responsible for my medicines or therapy
Sexual Functioning
1. Fatigue or lack of energy affecting your satisfaction
with your sex life
2. Pain affecting your satisfaction with your sex life
3. Ability to have children with a fertile partner
Copyright © 2012.
The PedsQL™ is available at http://www.pedsql.org/
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